Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended March 31, 2016
Unichem Laboratories Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended March 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholding for the Period Ended December 31, 2015
Unichem Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2015. For more details, kindly Click here Unichem gains on USFDA nod for Quetiapine Fumarate tablets
Quetiapine Fumarate is an atypical antipsychotic indicated for the treatment of Schizophrenia, Fixes Record Date for Interim Dividend
Unichem Laboratories Ltd has informed BSE that the Company has fixed March 19, 2016 as the Record Date for the purpose of payment of Interim Dividend.The said Interim Dividend shall be paid to the shareholders on March 28, 2016. Board declares Interim Dividend
Unichem Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on March 09, 2016, inter alia, has :1. Declared an interim dividend of Rs. 2/- (100%) per equity share of Rs. 2/- each;2. Allotted 2,025 Equity shares having a face value of Rs. 2/- each pursuant to exercise of options by eligible employees under the Employees Stock Option Scheme 2008.The meeting commenced at 12.00 noon and concluded at 1 p.m. Unichem Laboratories receives ANDA approval from USFDA for Quetiapine Fumarate Tablets
Unichem Laboratories Ltd has informed BSE regarding a Press Release dated March 09, 2016 titled "Unichem Laboratories receives ANDA approval from USFDA for Quetiapine Fumarate Tablets". Board to consider Interim Dividend
Unichem Laboratories Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on March 09, 2016, inter alia to consider and approve declaration of Interim Dividend.Further, in terms of the Company's Code of Conduct to Regulate, Conduct, Monitor and Report Trading by Insiders, formulated and adopted under the Securities and Exchange Board of India Prohibition of Insider Trading Regulations, 2015, the Trading... Investor Presentation
Unichem Laboratories Ltd has submitted to BSE a copy of Investor Presentation - Q3 & 9M FY 2016 Unichem Gets US Regulator Nod to Sell Prostate Drug
Drug firm Unichem Laboratories has received approval from the US health regulator to market alfuzosin hydrochloride extended release tablets, used in treating prostatic hyperlasia, in the American mar... Unichem Laboratories receives Final ANDA approval from USFDA for Alfuzosin Hydrochloride Extended-Release Tablets USP
Unichem Laboratories Ltd has informed BSE regarding a Press Release dated January 29, 2016 titled "Unichem Laboratories receives Final ANDA approval from USFDA for Alfuzosin Hydrochloride Extended-Release Tablets USP".